All In Biotech

Free tool

FAERS Monitor: Beleodaq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206256 or its brand name (Beleodaq, Belinostat). Reports on generic versions are filed under their own applications.

Reports

358

Serious

318

89% of reports

Hospitalization

158

Death reported

121

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression77
  • nausea59
  • anaemia49
  • death43
  • vomiting43
  • dyspnoea36
  • platelet count decreased33
  • fatigue32
  • constipation28
  • neutropenia26
  • diarrhoea25
  • white blood cell count decreased24
  • neutrophil count decreased23
  • pyrexia22
  • pneumonia19

Reports by year received

View as table
YearReports
20113
20131
201410
201512
20165
20176
20186
201912
202014
202170
202249
202357
202440
202548
202625

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,801 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal7738.331.42,770
neutrophil count decreasedSignal2333.222.3687
platelet count decreasedSignal3318.213.1522
anaemiaSignal4915.111.6637
white blood cell count decreasedSignal2413.08.8255
neutropeniaSignal2611.27.8234
constipationSignal287.55.3154
vomitingSignal435.44.1152
nauseaSignal594.43.5156
dyspnoeaSignal363.72.771
pyrexiaSignal223.72.542
pneumoniaSignal193.42.231
deathSignal432.92.255
fatigueSignal322.41.726
diarrhoeaSignal252.31.617

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.